Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
summarizeSummary
Regeneron has announced detailed positive results from the Phase 3 NIMBLE trial for its investigational drug Cemdisiran in generalized myasthenia gravis (gMG). The data, published in The Lancet and presented at the American Academy of Neurology, demonstrated rapid, deep, and sustained disease control with a convenient subcutaneous every 12-week dosing, meeting its primary and key secondary endpoints. This follows the initial positive topline data shared in August 2025, providing comprehensive validation of the drug's efficacy and safety profile. Crucially, a U.S. regulatory application has been submitted, positioning Cemdisiran as a potential first-in-class siRNA for gMG. This represents a significant pipeline advancement for Regeneron, potentially opening a new, material revenue stream. Investors will now focus on the regulatory review process and the upcoming investor event for further insights.
At the time of this announcement, REGN was trading at $742.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.5B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.